Hepion Pharmaceuticals, Inc. (HEPA)
0.066
-0.01
(-7.11%)
USD |
OTCM |
Sep 03, 16:00
Hepion Pharmaceuticals EPS Diluted (Quarterly) : -0.0771 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0771 |
| March 31, 2026 | -0.0698 |
| December 31, 2025 | -0.0565 |
| September 30, 2025 | -0.0407 |
| June 30, 2025 | -0.092 |
| March 31, 2025 | -2.152 |
| December 31, 2024 | -11.12 |
| September 30, 2024 | -0.7242 |
| June 30, 2024 | -0.6769 |
| March 31, 2024 | -0.5626 |
| December 31, 2023 | -2.423 |
| September 30, 2023 | -2.743 |
| June 30, 2023 | -3.680 |
| March 31, 2023 | -3.479 |
| December 31, 2022 | -2.610 |
| September 30, 2022 | -2.243 |
| June 30, 2022 | -5.224 |
| March 31, 2022 | -1.818 |
| December 31, 2021 | -2.552 |
| September 30, 2021 | -121.61 |
| June 30, 2021 | -100.58 |
| March 31, 2021 | -116.25 |
| December 31, 2020 | -3.095 |
| September 30, 2020 | -13.82 |
| Date | Value |
|---|---|
| June 30, 2020 | -11.63 |
| March 31, 2020 | -19.45 |
| December 31, 2019 | -10.07 |
| September 30, 2019 | -10.59 |
| June 30, 2019 | -149.63 |
| March 31, 2019 | -160.57 |
| December 31, 2018 | -187.03 |
| September 30, 2018 | -885.43 |
| June 30, 2018 | -528.95 |
| March 31, 2018 | -372.06 |
| September 30, 2017 | -8615.04 |
| March 31, 2017 | -430752.0 |
| June 30, 2016 | -1904.00 |
| March 31, 2016 | -1568.00 |
| December 31, 2015 | -1232.00 |
| September 30, 2015 | -2464.00 |
| June 30, 2015 | -2702.45 |
| March 31, 2015 | -3719.97 |
| December 31, 2014 | -4032.00 |
| September 30, 2014 | -784.00 |
| June 30, 2014 | 2655.30 |
| March 31, 2014 | -7056.00 |
| December 31, 2013 | -224.00 |
| September 30, 2013 | -224.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.248M |
| Total Expenses (Quarterly) | 1.248M |
| Enterprise Value | 1.988M |
| Earnings Yield | -369.8% |
| Normalized Earnings Yield | -367.12 |